Navigation Links
Accera, Inc. Launches Neuera Pharmaceuticals, Inc.
Date:4/15/2009

New Business Spin-off to Focus on Drug Development for Neurological Conditions

BROOMFIELD, Colo., April 15 /PRNewswire/ -- Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system (CNS) diseases, announced today the formation of Neuera Pharmaceuticals, Inc., a drug development company. The new company will focus on the discovery and development of proprietary small molecule drugs for acute and chronic neurological conditions where the mechanism of defective energy metabolism or hypometabolism is involved.

Neuera Pharmaceuticals will operate as a wholly owned subsidiary and will be spun out of Accera as a stand-alone company after the completion of a $12 million series A financing round. Existing Accera investors have already committed to participate in the capital raise. Some of Accera's management and staff will join the newly formed company, and the current small molecule pipeline at Accera including the preclinical compounds, AC-0523 and AC-8632, have been transferred to Neuera. In addition to in-house development of small molecules, Neuera Pharmaceuticals is actively pursuing the license or acquisition of late clinical-stage products for CNS diseases or conditions that complement the hypometabolism platform.

"The division of our pipeline and Axona(TM) product between two organizations allows each one to concentrate on the unique regulatory requirements for their respective class of products. Each company will be a regulatory and market pure play that is better appreciated by investors and the industry," said Steve Orndorff, Ph.D., Accera's founder and CEO. "Furthermore, we believe the success of Axona in the marketplace will provide a real world validation of the energy metabolism platform for Neuera Pharmaceuticals' pipeline development."

On March 2nd Accera launched Axona, a first-in-class medical food product for the clinical dietary managem
'/>"/>

SOURCE Accera, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Accera, Inc. to Present at Upcoming Investor Conferences
2. Dr. Thomas Werner Elected to Accera, Inc.s Board of Directors
3. Accera, Inc. Sponsors Alzheimers Associations 2009 ICAD Conference
4. Accera, Inc. Completes $35 Million Series C Financing
5. Accera, Inc. Names William T. Poncy Vice President of Commercial Development
6. Accera, Inc. to Present at the 4th Annual BIO Investor Forum
7. ChemAxon Launches Marvin and JChem Version 5.2; Web Services, native .NET API, Homology Groups, 3D Alignment and Structural Frameworks
8. US Oncology Launches New Web Site
9. Pharmaceutical Institute Launches New Training Series Focused on Managed Markets Excellence
10. Kibow Biotech, Inc. Launches Breakthrough Probiotic Dietary Supplement for Kidney Health in USA and Canada
11. Selexis Launches Biosimilar Cell Line Development Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)...  Turing Pharmaceuticals AG announced that life sciences executive ... MSc,  has joined the company as president of ... holds a medical degree as well as a ... accomplishments in the pharmaceutical industry, and extensive clinical ... played a leadership role in numerous programs for ...
(Date:6/1/2015)... June 1, 2015 ... announced the addition of the "Oxidative ... Services), Test Type (Indirect, Enzyme-based, Reactive Oxygen ... End Users - Global Forecast to 2020" ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , The ...
(Date:6/1/2015)... and YONGIN, South Korea , June ... that Green Cross Biotherapeutics Inc. (GCBT) kicked off construction ... on the Montreal Technoparc,s Saint-Laurent Campus. The CA$315 million ... projects in Canada in the ... first intravenous immunoglobulin (IVIG) and albumin manufacturing plant in ...
(Date:6/1/2015)... CHICAGO and RARITAN, N.J. ... & Development, LLC (Janssen) announced data from the ... significant improvement in progression-free survival (PFS) with trabectedin ... with advanced liposarcoma (LPS) or leiomyosarcoma (LMS) previously ... additional chemotherapy regimen. SAR3007 is the largest randomized ...
Breaking Biology Technology:Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3Oxidative Stress Assay Market 2015 - Global Forecast to 2020 2Green Cross Biotherapeutics Kicks Off Construction in Montreal 2Green Cross Biotherapeutics Kicks Off Construction in Montreal 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6
... for Talent is opening up. Tens of millions of people ... join, or are already in, the workforce - bringing expectations, ... Those organizations that can inspire the passion and harness the ... their competitors. Here's why. , ,Until recently, workers of ...
... note: Janet Dillione is president of the health services ... largest medical technology companies. She has something in common with Donna ... - both recently were named among the Top 25 women in ... are some excerpts from a recent WTN interview with Dillione. ...
... Court has issued several rulings that have eroded the strength ... v. AT&T , the Supreme Court delivered another blow by ... law governs domestically but does not rule the world. , , ... Court addressed Section 271(f) of the patent code, which prohibits a ...
Cached Biology Technology:Media-savvy workers: New front in the War for Talent 2Media-savvy workers: New front in the War for Talent 3Media-savvy workers: New front in the War for Talent 4Media-savvy workers: New front in the War for Talent 5Siemens health services president calls IT benefits unassailable 2Siemens health services president calls IT benefits unassailable 3Siemens health services president calls IT benefits unassailable 4Siemens health services president calls IT benefits unassailable 5Supreme Court limits foreign reach of U.S. patents 2Supreme Court limits foreign reach of U.S. patents 3Supreme Court limits foreign reach of U.S. patents 4
(Date:6/1/2015)... 2015 According to a new ... by Technology (Touch-based & Touchless), Application (Consumer Electronics, Automotive, ... Geography - Global Forecast to 2020", published by MarketsandMarkets, ... to reach $23.55 Billion by 2020, at a CAGR ... Browse 83 market data T ables and   ...
(Date:6/1/2015)... 2015 According to a ... by Application (Government, Military & Defense, Healthcare, Banking ... Security), Technology (Face Recognition, Fingerprint Recognition, Iris Recognition, ... and Others), Function (Contact and Non-Contact) & Geography ... Europe , APAC, Row) - Global Forecast ...
(Date:5/29/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ) has ... Market by Solution, by Software, by Hardware, by ... report to their offering. The last ... more efficient and cost effective. This has helped ... the commercial sector. The development of 3D facial ...
Breaking Biology News(10 mins):Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 2Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 3Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 4Next Generation Biometrics Market Worth $24,448.84 Million by 2020 2Next Generation Biometrics Market Worth $24,448.84 Million by 2020 3Next Generation Biometrics Market Worth $24,448.84 Million by 2020 4Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2
... Jrgen Kjems and Morten Trillingsgaard Ven, Department of Molecular ... contribute to an article on microRNA-128 just published in ... was possible to control the amount of microRNA-128 in ... "If microRNA-128 is kept down in these neurons in ...
... Ariz. A group of researchers from Arizona State University ... in the study of human proteins that could open up ... work is being reported in this week,s Science ... G-protein-coupled receptors," the team reports that they have been successful ...
... New York have reported the successful transformation of vegetable ... a structuring agent. The findings portend the development of ... acids, which have been linked to coronary artery disease, ... College Professor of Chemistry George John, tested two sugar ...
Cached Biology News:New research provides insight into epilepsy 2ASU researchers develop new device to help image key proteins at room temperature 2ASU researchers develop new device to help image key proteins at room temperature 3CCNY chemists use sugar-based gelators to solidify vegetable oils 2
... of your microarray data using Asuragens bioinformatics ... from consultation to extensive data analysis using ... our expertise in combination with the Gene ... microarray experiments., ,Normalization and basic statistical analysis ...
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ...
... (OSM) is a pleiotropic cytokine produced by ... cells. OSM inhibits the growth of some ... smooth muscle and Kaposis sarcoma cell proliferation, ... density lipoprotein receptor expression on hepatoma cells. ...
... syringe pump series combines Harvard Apparatuss best pump ... a wide range of configuration options. A lookup ... of syringes from all the major manufacturers. A ... the pertinent information from across the lab. All ...
Biology Products: